Vivos Therapeutics Inc. has filed a prospectus supplement with the Securities and Exchange Commission (SEC), allowing the company to continue selling its common stock under an At The Market (ATM) Offering Agreement. This arrangement, facilitated through H.C. Wainwright & Co., LLC as the sales agent, enables Vivos to offer and sell shares up to an aggregate value of $5,830,572. The sale of these shares will be conducted under a shelf registration statement, which was initially filed in February and declared effective by the SEC in September. The prospectus supplements the ongoing registration, ensuring compliance with the Securities Act of 1933.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-027210), on September 12, 2025, and is solely responsible for the information contained therein.